



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Bortezomib (Standard)

Cat. No.:	HY-10227R
CAS No.:	179324-69-7
Molecular Formula:	C <sub>19</sub> H <sub>25</sub> BN <sub>4</sub> O <sub>4</sub>
Molecular Weight:	384.24
Target:	Apoptosis; Autophagy; NF-κB; Proteasome
Pathway:	Apoptosis; Autophagy; NF-κB; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K <sub>i</sub> =0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	Ki: 0.6 nM (20S proteasome) <sup>[1]</sup>

### REFERENCES

- [1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. *Cancer Res.* 1999 Jun 1;59(11):2615-22.
- [2]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. *Am J Cancer Res.* 2011;1(7):913-24.
- [3]. Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. *Blood.* 2006 Jan 1;107(1):257-64.
- [4]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. *Mol Med Rep.* 2010 Mar-Apr;3(2):333-9.
- [5]. Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. *Discov Med.* 2011 Dec;12(67):471-80.
- [6]. Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. *J Biol Chem.* 2006 Jan 13;281(2):1107-18.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA